@article{ba61b979779c4c0e82e5fa2e38cb703d,
title = "The author and colleagues reply",
author = "Gordon, \{Kenneth B.\} and Colombel, \{Jean Frederic\} and Hardin, \{Dana S.\}",
note = "Funding Information: Since publication of his article, Dr. Gordon reports no further potential conflict of interest. Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving speaking fees from AbbVie, Amgen, Ferring Pharmaceuticals, Shire, and Takeda; receiving honoraria for advisory-board membership from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Eli Lilly, Medimmune, Merck, Pfizer, Protagonist Therapeutics, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag, and Theravance Biopharma; and being a shareholder of Intestinal Biotech Development and Genfit. Dr. Hardin reports being an employee and shareholder of Eli Lilly.",
year = "2016",
month = nov,
day = "24",
doi = "10.1056/NEJMc1610828",
language = "English",
volume = "375",
pages = "2102",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "21",
}